Janssen, GSK China HIV Approvals Show Increased Transparency
This article was originally published in The Pink Sheet Daily
Executive Summary
In a rare move and further indication of a determination to break away from its past, China FDA has made timely public announcements of the approval of two new treatments for HIV that it deems to be breakthroughs, although it could be some time before they reach the market.
You may also be interested in...
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.